Reasons for Unsuccessful Recruitment of Children with Atopic Dermatitis in Primary Care in the Netherlands to a Cohort Study with an Embedded Pragmatic, Randomised Controlled Open-label Trial: a Survey

Overview

Journal BMJ Open

Specialty General Medicine

Date 2024 May 16

PMID 38754875

Authors

Karlijn F van Halewijn

Arthur M Bohnen

Suzanne G M A Pasmans

Patrick J E Bindels

Gijs Elshout

Affiliations

Soon will be listed here.

Abstract

Background: The Rotterdam Eczema Study was an observational cohort study with an embedded pragmatic randomised controlled open-label trial. It was conducted in children with atopic dermatitis (AD) in the Dutch primary care system. The objective of the trial was to determine whether a potent topical corticosteroid (TCS) is more effective than a low-potency TCS.

Objective: We are aiming to communicate transparently about the poor recruitment for the trial part and to explore the reasons why recruitment was weak.

Design: We used a survey to find out what patients in the cohort did when they experienced a flare-up.

Methods: Descriptive statistics were used to present the baseline characteristics of participants in the trial and the results of the survey.

Results: In total, 367 patients were included in the cohort. Of these, 32 were randomly assigned to a trial treatment; they had a median age of 4.0 years (IQR 2.0-9.8). A total of 69 of the 86 children (80.2%) who could participate in the survey responded. 39 (56.5%) suffered a flare-up during the follow-up (making them potentially eligible for inclusion in the trial). 26 out of 39 (66.7%) increased their use of an emollient and/or TCS themselves. Only 12 of the 39 (30.7%) contacted their general practitioner (GP) as instructed in the study protocol, but 8 out of these 12 did not meet the inclusion criteria for the trial.

Conclusion: The main reason why cohort participants did not take part in the trial was that they did not contact their GPs when they experienced an AD flare-up. Furthermore, the majority of patients who contacted their GPs did not match the inclusion criteria of the trial. We expect that the lessons learnt from this study will be useful when developing future studies of children with AD in primary care.

Citing Articles

Effectiveness of potent topical corticosteroids versus mild ones in primary care for children with moderate flare-ups of atopic dermatitis; results of a randomised controlled trial.

van Halewijn K, Elshout G, Bohnen A, Bindels P, Pasmans S BMJ Open. 2025; 14(12):e078940.

PMID: 39806719 PMC: 11667327. DOI: 10.1136/bmjopen-2023-078940.

References

van Halewijn K, Lahnstein T, Bohnen A, van den Berg P, Pasmans S, Bindels P . Recommendations for emollients, bathing and topical corticosteroids for the treatment of atopic dermatitis: a systematic review of guidelines. Eur J Dermatol. 2022; 32(1):113-123. DOI: 10.1684/ejd.2022.4197. View

Spuls P, Gerbens L, Simpson E, Apfelbacher C, Chalmers J, Thomas K . Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement. Br J Dermatol. 2016; 176(4):979-984. DOI: 10.1111/bjd.15179. View

Ragamin A, Schappin R, Nguyen N, Nouwen A, Hoekstra L, Schuttelaar M . Remote severity assessment in atopic dermatitis: Validity and reliability of the remote Eczema Area and Severity Index and Self-Administered Eczema Area and Severity Index. JAAD Int. 2023; 13:184-191. PMC: 10630629. DOI: 10.1016/j.jdin.2023.07.019. View

Briel M, Elger B, McLennan S, Schandelmaier S, von Elm E, Satalkar P . Exploring reasons for recruitment failure in clinical trials: a qualitative study with clinical trial stakeholders in Switzerland, Germany, and Canada. Trials. 2021; 22(1):844. PMC: 8613940. DOI: 10.1186/s13063-021-05818-0. View

Wolkerstorfer A, de Waard van der Spek F, Glazenburg E, Mulder P, Oranje A . Scoring the severity of atopic dermatitis: three item severity score as a rough system for daily practice and as a pre-screening tool for studies. Acta Derm Venereol. 1999; 79(5):356-9. DOI: 10.1080/000155599750010256. View

Baker A, Mitchell E, Thomas K . A practical guide to implementing a successful social media recruitment strategy: lessons from the Eczema Monitoring Online trial. Trials. 2022; 23(1):905. PMC: 9612595. DOI: 10.1186/s13063-022-06839-z. View

Knapp P, Moe-Byrne T, Martin-Kerry J, Sheridan R, Roche J, Coleman E . Providing multimedia information to children and young people increases recruitment to trials: pre-planned meta-analysis of SWATs. BMC Med. 2023; 21(1):244. PMC: 10320935. DOI: 10.1186/s12916-023-02936-1. View

Butler C, Hobbs F, Gbinigie O, Rahman N, Hayward G, Richards D . Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet. 2022; 401(10373):281-293. PMC: 9779781. DOI: 10.1016/S0140-6736(22)02597-1. View

van Halewijn K, van der Most F, Bohnen A, Pasmans S, Bindels P, Elshout G . Atopic Dermatitis in Children in the General Population: Baseline Characteristics, Medication Use, and Severity Measures in the Rotterdam Eczema Study. Dermatitis. 2023; 35(1):61-69. DOI: 10.1089/derm.2022.0040. View

10.

Pols D, Nielen M, Bohnen A, Korevaar J, Bindels P . Atopic children and use of prescribed medication: A comprehensive study in general practice. PLoS One. 2017; 12(8):e0182664. PMC: 5570284. DOI: 10.1371/journal.pone.0182664. View

11.

Lax S, Harvey J, Axon E, Howells L, Santer M, Ridd M . Strategies for using topical corticosteroids in children and adults with eczema. Cochrane Database Syst Rev. 2022; 3:CD013356. PMC: 8916090. DOI: 10.1002/14651858.CD013356.pub2. View

12.

van Halewijn K, Bohnen A, van den Berg P, Pasmans S, Bindels P, Elshout G . Different potencies of topical corticosteroids for a better treatment strategy in children with atopic dermatitis (the Rotterdam Eczema study): protocol for an observational cohort study with an embedded randomised open-label controlled trial. BMJ Open. 2019; 9(6):e027239. PMC: 6588953. DOI: 10.1136/bmjopen-2018-027239. View

13.

von Kobyletzki L, Ballardini N, Henrohn D, Neary M, Ortsater G, Geale K . Care pathways in atopic dermatitis: a retrospective population-based cohort study. J Eur Acad Dermatol Venereol. 2022; 36(9):1456-1466. PMC: 9542393. DOI: 10.1111/jdv.18185. View

14.

Briel M, Olu K, von Elm E, Kasenda B, Alturki R, Agarwal A . A systematic review of discontinued trials suggested that most reasons for recruitment failure were preventable. J Clin Epidemiol. 2016; 80:8-15. DOI: 10.1016/j.jclinepi.2016.07.016. View

15.

van der Worp H, Loohuis A, Flohil I, Kollen B, Wessels N, Blanker M . Recruitment through media and general practitioners resulted in comparable samples in an RCT on incontinence. J Clin Epidemiol. 2019; 119:85-91. DOI: 10.1016/j.jclinepi.2019.12.001. View

16.

McDonald A, Knight R, Campbell M, Entwistle V, Grant A, Cook J . What influences recruitment to randomised controlled trials? A review of trials funded by two UK funding agencies. Trials. 2006; 7:9. PMC: 1475627. DOI: 10.1186/1745-6215-7-9. View

17.

Treweek S, Pitkethly M, Cook J, Fraser C, Mitchell E, Sullivan F . Strategies to improve recruitment to randomised trials. Cochrane Database Syst Rev. 2018; 2:MR000013. PMC: 7078793. DOI: 10.1002/14651858.MR000013.pub6. View

18.

Moynihan R, Sanders S, Michaleff Z, Scott A, Clark J, To E . Impact of COVID-19 pandemic on utilisation of healthcare services: a systematic review. BMJ Open. 2021; 11(3):e045343. PMC: 7969768. DOI: 10.1136/bmjopen-2020-045343. View

19.

Ali Z, Chiriac A, Bjerre-Christensen T, Isberg A, Dahiya P, Manole I . Mild to moderate atopic dermatitis severity can be reliably assessed using smartphone-photographs taken by the patient at home: A validation study. Skin Res Technol. 2022; 28(2):336-341. PMC: 9907712. DOI: 10.1111/srt.13136. View